Gene · 1859
Papers3,825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,825
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DYRK1A in blood and immune function: implications in leukemia, inflammatory disorders, infection and Down syndrome. | Front Cell Dev Biol | 2025 | 40519271 | PubTator, text mining | PubMed |
| Chaperone-mediated autophagy directs a dual mechanism to balance premature senescence and senolysis to prevent intervertebral disc degeneration. | Bone Res | 2025 | 40506462 | PubTator, text mining | PubMed |
| The role of Goldilocks protein kinase DYRK1A in embryonic development. | Dev Biol | 2025 | 40505942 | PubTator, text mining | PubMed |
| Structure-guided discovery of tau-phosphorylating kinase DYRK1A inhibitors for therapeutic targeting of neuroinflammatory diseases: Insights from microsecond MD simulation and MMPBSA analyses. | Biochem Biophys Res Commun | 2025 | 40505550 | PubTator, text mining | PubMed |
| Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease. | Alzheimers Dement | 2025 | 40501099 | PubTator, text mining | PubMed |
| Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A. | Nat Genet | 2025 | 40490510 | PubTator, text mining | PubMed |
| Temperature vaulting: A method for screening of slow- and tight-binding inhibitors that selectively target kinases in their non-native state. | Eur J Med Chem | 2025 | 40412300 | PubTator, text mining | PubMed |
| DYRK1A syndrome presenting with a familial exudative vitreoretinopathy (FEVR)-like retinovascular phenotype. | Ophthalmic Genet | 2025 | 40405340 | PubTator, text mining | PubMed |
| DYRK1A modulates fear memory formation via epigenetic modification. | Mol Brain | 2025 | 40390093 | PubTator, text mining | PubMed |
| Recent advances in nuclear actin research. | Nucleus | 2025 | 40320716 | PubTator, text mining | PubMed |
| AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors. | J Med Chem | 2025 | 40317470 | PubTator, text mining | PubMed |
| Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease. | Alzheimers Dement | 2025 | 40275833 | PubTator, text mining | PubMed |
| A review of machine learning methods for imbalanced data challenges in chemistry. | Chem Sci | 2025 | 40271022 | PubTator, text mining | PubMed |
| Structural Dynamics and Network Pharmacology for the Discovery of Inhibitors Targeting DYRK1 A in Neurological Disorders. | Mol Neurobiol | 2025 | 40261606 | PubTator, text mining | PubMed |
| Prioritizing Parkinson's disease risk genes in genome-wide association loci. | NPJ Parkinsons Dis | 2025 | 40240380 | PubTator, text mining | PubMed |
| Clinical and molecular overlap between nucleotide excision repair (NER) disorders and DYRK1A haploinsufficiency syndrome. | Front Neurosci | 2025 | 40206408 | PubTator, text mining | PubMed |
| DYRK1A roles in human neural progenitors. | Front Neurosci | 2025 | 40182141 | PubTator, text mining | PubMed |
| DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition. | Leukemia | 2025 | 40148558 | PubTator, text mining | PubMed |
| Benzamide Derivatives of Thioacridine as DYRK2 and DYRK3 Dual Inhibitors. | ChemMedChem | 2025 | 40145237 | PubTator, text mining | PubMed |
| TOM1L1 mediated the sort of tumor suppressive miR-378a-3p into exosomes and the excretion out of cells to promote ESCC progression. | Cancer Gene Ther | 2025 | 40123000 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1859/papers?page=8